Place: Edgewater Inn, 2411 Alaskan Way-Pier 67, Seattle, Washington 98121, telephone 206/728–7000, FAX 206/441–4119.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 150 people.

Background: A Memorandum of Understanding (MOU) was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

In addition, under an MOU signed in December 1990 with DOE, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production and use. HHS delegated program responsibility to CDC.

Purpose: The purpose of this meeting is to receive updates from the Inter-tribal Council on Hanford Health Projects; receive updates and clarification from ATSDR and CDC representatives on outstanding issues; discuss with Agency personnel, issues relevant to the Technical Steering Panel of the Hanford Environmental Dose Reconstruction Project; receive a report on the ''Workshop on Radiation Health Risks for Hanford: Considerations for Medical Monitoring''; receive reports from the Outreach, Public Health Activities, and Health Studies Work Groups; and receive a presentation on ''other contaminants of concern.''

Matters to be Discussed: Agenda items will include ATSDR's and CDC's updates, a discussion of ''Popular Epidemiology,'' and solicitation of concerns the Subcommittee wants ATSDR and CDC to address.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Linda A. Carnes, Health Council Advisor, ATSDR, E–28, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639–0730, FAX 404/639–0759.

Dated: November 3, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–27771 Filed 11–8–95; 8:45 am]

BILLING CODE 4163–70–M

Food and Drug Administration

[Docket No. 88N–0394]

Generic Animal Drug and Patent Term Restoration Act; Ninth Policy Letter; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a ninth policy letter, dated June 27, 1995, concerning implementation of the Generic Animal Drug and Patent Term Restoration Act (GADPTRA). The ninth policy letter states the revised policy of the Center for Veterinary Medicine (CVM) on the environmental information to be submitted by sponsors for generic animal drug products. The agency is soliciting comments on the policy letter.

DATES: Written comments may be submitted at any time regarding this or previous policy letters or implementation of GADPTRA in general.

ADDRESSES: Submit written requests for single copies of the ninth policy letter to the Industry Information Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send two self-addressed adhesive labels to assist that office in processing your request. Submit written comments on the ninth policy letter to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. The ninth policy letter and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Charles E. Eirkson, Center for Veterinary Medicine (HFV–152), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1683.

SUPPLEMENTARY INFORMATION: On November 16, 1988, President Reagan signed GADPTRA into law (Pub. L. 100–670). GADPTRA amends the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 *et seq.*) by extending the generic approval system to copies of new animal drugs that were approved after October 10, 1962, and provides patent extension for certain animal drugs.

FDA has published notices of availability for eight policy letters concerning implementation of GADPTRA. A list of the publication dates and topics of the first five letters was published in the Federal Register of June 18, 1990 (55 FR 24645). In the Federal Register of October 31, 1990 (55 FR 45860), FDA published a notice of availability of the sixth letter dated October 17, 1990. In the Federal Register of April 15, 1991 (56 FR 15083), FDA published a notice of availability of the seventh policy letter dated March 20, 1991. In the Federal Register of August 21, 1991 (56 FR 41561), FDA published a notice of availability of the eighth policy letter dated July 23, 1991.

FDA is now announcing the availability of a ninth policy letter dated June 27, 1995, which is a revision of the second policy letter, dated June 7, 1989. The second letter notified sponsors to submit an environmental assessment (EA) that addresses the environmental impact associated with the manufacture of the generic bulk drug and finished product. Based on the experience acquired from reviewing a considerable number of these EA's with no significant environmental impact identified, CVM has confirmed that there is no reason to believe the manufacture of generic animal drugs may significantly affect the environment and decided, in most cases, CVM will categorically exclude generic animal drug applications from preparation of an EA under 21 CFR 25.24(d)(1).

This policy does not create or confer any rights, privileges, or benefits for or on any person, nor does it operate to bind FDA in any way. The agency anticipates that changes in these policy statements may occur in the future. When and if changes are made, copies of the revised policy statements will be placed on display in the Dockets Management Branch (address above) and a notice of availability will be published in the Federal Register.

In addition, the subjects contained in these policy statements may be addressed in the regulations that will implement GADPTRA. Comments submitted in response to this notice will be considered in the drafting of the proposed regulations.

Dated: November 3, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–27801 Filed 11–8–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0356]

Schering Corp., et al.; Withdrawal of Approval of Seven Abbreviated Antibiotic Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of seven abbreviated antibiotic applications (AADA's). The holders of the AADA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: November 9, 1995.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: The holders of the AADA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

AADA No.	Drug	Applicant
61–979	Sisomicin Sulfate USP	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
62–119	Doxycycline Hyclate Capsules, 50 milligrams (mg) and 100 mg	Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233.
62–267	Gentamicin Sulfate USP	Chinoin Pharmaceutical and Chemical Works Co. Ltd., c/o Forum Products, Inc., 33 Flying Point Rd., Southampton, NY 11968.
62–403	Nystatin USP	Do.
62–406	Sterile Chloramphenicol Sodium Succinate USP	Elkins-Sinn Pharmaceuticals, Two Esterbrook Lane, Cherry Hill, NJ 08003–4099.
62–534	Gentamicin Sulfate Ointment USP	Pharmaderm, 60 Baylis Rd., Melville, NY 11747.
62–618	Erythromycin Delayed-Release Capsules USP	Parke-Davis, 2800 Plymouth Rd., Ann Arbor, MI 48105.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the AADA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective November 9, 1995.

Dated: October 30, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95–27802 Filed 11–8–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR–3778–N–62]

Federal Property Suitable as Facilities to Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

EFFECTIVE DATE: November 9, 1995.

FOR FURTHER INFORMATION CONTACT:

Mark Johnston, Department of Housing and Urban Development, Room 7256, 451 Seventh Street SW., Washington, DC 20410; telephone (202) 708–1226; TDD number for the hearing- and speech-impaired (202) 708–2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless* v. *Veterans Administration*, No. 88–2503–OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: November 3, 1995.

Jacquie M. Lawing,

Deputy Assistant Secretary for Economic Development.

[FR Doc. 95–27769 Filed 11–8–95; 8:45 am]

BILLING CODE 4210–29–M

Office of the Secretary

[Docket No. FR–3918–N–06]

Privacy Act of 1974; Proposed Amendment to System of Records

AGENCY: Department of Housing and Urban Development (HUD).

ACTION: Notification of proposed amendment to one of the existing system of records.

SUMMARY: Pursuant to the provisions of the Privacy Act of 1974, 5 U.S.C. 552a, the Department of Housing and Urban Development is giving notice that it intends to amend the Privacy Act's Single Family Case Files (HUD/Dept–46) system of records.

EFFECTIVE DATE: This amendment will be effective without further notice on December 11, 1995, unless comments are received that would result in a contrary determination.

ADDRESSES: Interested persons are invited to submit comments regarding the proposed amendment to the Rules Docket Clerk, Office of General Counsel, 451 Seventh Street, SW., Washington, DC 20410–0500. Communications should refer to the above docket number and title. Facsimile (FAX) comments are not acceptable. A copy of each communication submitted will be available for public inspection and copying between 7:30 a.m. and 5:30 p.m. weekdays at the above address.

FOR FURTHER INFORMATION CONTACT:

Jeanette Smith, Departmental Privacy Act Officer, at (202) 708–2374. This is not a toll-free number.

SUPPLEMENTARY INFORMATION: HUD/Dept–46 is being amended to allow the release of mortgage origination and default/claim information to financial institutions and computer software companies for the purpose of conducting automated underwriting,